Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Morabito · SciRah

Researcher profile · Semantic Scholar

F. Morabito

Share profile

F. Morabito — researcher profile on SciRah

h-index: 57
Works: 553
Citations: 13K

Most-cited papers

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.
A. Condoluci, L. Terzi di Bergamo, P. Langerbeins, M. Hoechstetter +42 more
2020Blood125 citations Open access
Semantic Scholar
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
P. Monti, P. Menichini, Andrea Speciale, G. Cutrona +9 more
2020Frontiers in Oncology82 citations Open access
Semantic Scholar
Iron chelation therapy
A. Bruzzese, E. Martino, F. Mendicino, E. Lucia +8 more
2023European Journal of Haematology57 citations
Semantic Scholar
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
P. Tacchetti, L. Pantani, F. Patriarca, M. Petrucci +93 more
2020The Lancet Haematology44 citations
Semantic Scholar
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice
S. Galimberti, E. Genuardi, F. Mazziotta, L. Iovino +5 more
2019Frontiers in Oncology44 citations Open access
Semantic Scholar
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
C. Botta, F. Mendicino, E. Martino, E. Vigna +5 more
2021Cancers42 citations Open access
Semantic Scholar
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
P. Menichini, P. Monti, Andrea Speciale, G. Cutrona +10 more
2021Cells41 citations Open access
Semantic Scholar
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
R. Bomben, F. Rossi, F. Vit, T. Bittolo +33 more
2021Clinical Cancer Research40 citations Open access
Semantic Scholar
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, F. Morabito, N. Giuliani, C. Terragna +25 more
2019Journal of Hematology & Oncology34 citations Open access
Semantic Scholar
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
K. Todoerti, D. Ronchetti, V. Favasuli, Francesco Maura +4 more
2021Haematologica33 citations Open access
Semantic Scholar
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
M. Gentile, G. Specchia, D. Derudas, M. Galli +52 more
2020Haematologica29 citations Open access
Semantic Scholar
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
R. Bomben, F. Rossi, F. Vit, T. Bittolo +25 more
2023Leukemia23 citations Open access
Semantic Scholar
Teclistamab‐cqyv in multiple myeloma
E. Martino, A. Bruzzese, C. Labanca, F. Mendicino +6 more
2023European Journal of Haematology22 citations Open access
Semantic Scholar
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
M. Gentile, E. Vigna, S. Palmieri, M. Galli +43 more
2023Haematologica22 citations Open access
Semantic Scholar
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
C. Botta, E. Martino, C. Conticello, F. Mendicino +8 more
2021Frontiers in Oncology22 citations Open access
Semantic Scholar
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
M. Gentile, F. Morabito, G. del Poeta, F. Mauro +35 more
2020Leukemia22 citations
Semantic Scholar
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
Sara Raponi, Caterina Ilari, I. Della Starza, L. Cappelli +15 more
2020British Journal of Haematology22 citations Open access
Semantic Scholar
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines
P. Giannoni, C. Marini, G. Cutrona, S. Matis +17 more
2020Haematologica22 citations Open access
Semantic Scholar
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
F. Morabito, Carlo Adornetto, P. Monti, A. Amaro +13 more
2023Frontiers in Oncology21 citations Open access
Semantic Scholar
Belantamab mafodotin in multiple myeloma
E. Martino, A. Bruzzese, E. Iaccino, C. Labanca +8 more
2023Expert Opinion on Biological Therapy21 citations Open access
Semantic Scholar
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
F. Autore, P. Strati, I. Innocenti, F. Corrente +26 more
2019Cancers21 citations Open access
Semantic Scholar
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
Jared A. Cohen, F. Rossi, A. Zucchetto, R. Bomben +25 more
2019Haematologica21 citations Open access
Semantic Scholar
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
F. Patriarca, B. Bruno, H. Einsele, F. Spina +8 more
2018Biology of Blood and Marrow Transplantation21 citations Open access
Semantic Scholar
Comparison between the CLL‐IPI and the Barcelona‐Brno prognostic model: Analysis of 1299 newly diagnosed cases
M. Gentile, T. Shanafelt, F. Mauro, L. Laurenti +19 more
2018American journal of hematology/oncology20 citations Open access
Semantic Scholar
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
F. Morabito, T. Shanafelt, M. Gentile, G. Reda +20 more
2018American journal of hematology/oncology19 citations Open access
Semantic Scholar
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies
E. Martino, A. Bruzzese, C. Labanca, F. Mendicino +9 more
2024Expert Opinion on Investigational Drugs18 citations
Semantic Scholar
Lenalidomide for the treatment of mantle cell lymphoma
F. Morabito, Mamdouh Skafi, A. Recchia, Aya Kashkeesh +6 more
2019Expert Opinion on Pharmacotherapy18 citations
Semantic Scholar
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
E. Vigna, Annamaria Petrungaro, A. Perri, D. Terzi +9 more
2018Transfusion and Apheresis Science18 citations
Semantic Scholar
Chemotherapy-based regimens in multiple myeloma in 2020.
M. Gentile, F. Morabito, M. Martino, E. Vigna +4 more
2020Panminerva Medica (Testo stampato)17 citations
Semantic Scholar
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
A. Bruzzese, D. Derudas, M. Galli, E. Martino +56 more
2022Hematological Oncology16 citations Open access
Semantic Scholar
Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
D. Bagnara, Catherine Tang, Jennifer R. Brown, Siddha N. Kasar +15 more
2021Frontiers in Oncology16 citations Open access
Semantic Scholar
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
P. Monti, M. Lionetti, Giuseppa De Luca, P. Menichini +16 more
2020Scientific Reports16 citations Open access
Semantic Scholar
Isatuximab in multiple myeloma
E. Martino, A. Bruzzese, E. Iaccino, F. Mendicino +7 more
2023Expert Opinion on Biological Therapy15 citations
Semantic Scholar
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
E. Martino, C. Conticello, E. Zamagni, V. Pavone +29 more
2022Hematological Oncology15 citations
Semantic Scholar
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
R. De Filippi, F. Morabito, A. Santoro, G. Tripepi +6 more
2021Journal of Translational Medicine14 citations Open access
Semantic Scholar
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
D. Ronchetti, V. Favasuli, P. Monti, G. Cutrona +15 more
2020Non-Coding RNA14 citations Open access
Semantic Scholar
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
E. Barbieri, E. Martino, E. Rivolti, M. Quaresima +4 more
2024Expert Opinion on Biological Therapy13 citations
Semantic Scholar
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
S. Matis, A. Recchia, M. Colombo, Martina Cardillo +28 more
2022Blood Advances13 citations Open access
Semantic Scholar
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
F. Morabito, G. del Poeta, F. Mauro, G. Reda +44 more
2021American journal of hematology/oncology13 citations Open access
Semantic Scholar
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
F. Morabito, G. Tripepi, G. del Poeta, F. Mauro +43 more
2021American journal of hematology/oncology13 citations Open access
Semantic Scholar
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors
F. Morabito, M. Gentile, P. Monti, A. Recchia +18 more
2020Expert Opinion on Investigational Drugs13 citations Open access
Semantic Scholar
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia
G. Reda, R. Cassin, M. Gentile, F. Mauro +9 more
2019Leukemia13 citations
Semantic Scholar
Elotuzumab in multiple myeloma
A. Bruzzese, E. Martino, E. Vigna, E. Iaccino +7 more
2022Expert Opinion on Biological Therapy12 citations Open access
Semantic Scholar
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
F. Morabito, G. Tripepi, E. Martino, E. Vigna +10 more
2021Drug Design, Development and Therapy12 citations Open access
Semantic Scholar
Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment
M. Gentile, T. Shanafelt, F. Mauro, G. Reda +33 more
2018European Journal of Haematology12 citations Open access
Semantic Scholar
Selinexor in multiple myeloma
E. Martino, E. Vigna, A. Bruzzese, C. Labanca +8 more
2024Expert Opinion on Pharmacotherapy11 citations
Semantic Scholar
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
F. Morabito, E. Zamagni, C. Conticello, V. Pavone +40 more
2021European Journal of Haematology11 citations Open access
Semantic Scholar
Venetoclax in acute myeloid leukemia
A. Bruzzese, E. Martino, F. Mendicino, E. Lucia +5 more
2023Expert Opinion on Investigational Drugs10 citations Open access
Semantic Scholar
Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
D. Bagnara, M. Colombo, D. Reverberi, S. Matis +14 more
2022Frontiers in Oncology10 citations Open access
Semantic Scholar
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
F. Morabito, G. Tripepi, R. Moia, A. Recchia +21 more
2021Frontiers in Oncology10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Gentile×38
Invite
M. Gentile — researcher profile on SciRah
A. Neri×31
Invite
A. Neri — researcher profile on SciRah
E. Vigna×26
Invite
E. Vigna — researcher profile on SciRah
E. Martino×21
Invite
E. Martino — researcher profile on SciRah

×19

Invite

G. Cutrona — researcher profile on SciRah

M. Ferrarini×17

Invite

M. Ferrarini — researcher profile on SciRah

F. Mendicino×16

Invite

F. Mendicino — researcher profile on SciRah

F. Di Raimondo×16

Invite

F. Di Raimondo — researcher profile on SciRah

Invite

G. Tripepi — researcher profile on SciRah

A. Bruzzese×12

Invite

A. Bruzzese — researcher profile on SciRah

Invite

A. Recchia — researcher profile on SciRah

Invite

F. Mauro — researcher profile on SciRah